Moderna Inc. has made all necessary submissions required by the U.S. Food and Drug Administration for emergency use authorization of the company’s COVID-19 vaccine in adolescents and children.
Inovio Pharmaceuticals announced a leadership change at the helm and the discontinuation of a Phase III COVID-19 vaccine study.
Just as Emergent BioSolutions looked to be making some headway in course corrections following a production mishap that ruined millions of doses of Johnson & Johnson’s COVID-19 vaccine, new information indicates the Maryland-based company sought to hide the deficiencies from federal regulators, all while touting its manufacturing capabilities, according to a BioSpace article.
Pfizer Inc. said on May 10 the company will pay $11.6 billion to buy Biohaven Pharmaceutical Holding Co., making a big bet on its ability to boost sales of the top-selling pill in a new class of migraine drugs.
Novavax Inc.’s shares plunged nearly 20 percent in premarket trading on May 10 due to uncertainty over global demand for the company’s COVID-19 vaccine following a slow start to deliveries.
Texas doctor calls U.S. COVID deaths nearing 1 million ‘mindblowing’
“Long-Haul” COVID-19, Asymptomatic Patients, BNT162b2 (Pfizer and BioNTech), Breakthrough COVID-19, Coronavirus Disease (COVID-19) Pandemic, Coronavirus Disease 2019 (COVID-19), Coronavirus Restrictions, Coronavirus surge, Coronavirus Vaccines, COVID guidelines, COVID-19 anti-vaxxers, Covid-19 asymptomatic infections, COVID-19 cases, COVID-19 Deaths, Covid-19 fatality rate, COVID-19 inoculations, COVID-19 misinformation, COVID-19 Prevention Measures, COVID-19 protocols, COVID-19 recommendations, COVID-19 risk, COVID-19 Severe Complications, COVID-19 Vaccines, Deaths, Janssen COVID-19 Vaccine (J&J), Mask-wearing, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Pandemics, Therapeutics, Vaccines, Vaxzevria (previously COVID-19 Vaccine AstraZeneca)In the early days of the COVID-19 pandemic, pulmonologist Joseph Varon offered an opinion that made headlines around the world and went viral on social media. Varon was fighting two wars, he said: one against COVID and one against stupidity.
BioNTech continues to build on the success of the company’s mRNA COVID-19 vaccine co-developed with Pfizer, rapidly expanding its investigational pipeline to include additional infectious diseases and oncology with a first-in-class CAR-T program in solid tumors.
Moderna urges court to dismiss ongoing vaccine patent issues
Coronavirus Vaccines, Lipid Nanoparticles (LNPs), Moderna, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Nanoparticles, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, NIH, Patent Challenges, Patent Claims, Patents, TherapeuticsModerna is still fending off patent challenges over the lipid nanoparticle delivery system used in the company’s COVID-19 vaccine, Spikevax.
BioNTech’s first-quarter 2022 sales and earnings more than tripled due to demand for the COVID-19 vaccine the company developed with Pfizer, but the German biotech firm is still forecasting a full-year decline in vaccine sales.
COVID vaccine makers shift focus to boosters
AstraZeneca, Biopharma Companies, BNT162b2 (Pfizer and BioNTech), Coronavirus Vaccines, COVID vaccine mandates, COVID-19 booster shots, COVID-19 shots, COVID-19 Vaccines, CureVac, GlaxoSmithKline, Janssen, Janssen COVID-19 Vaccine (J&J), Johnson & Johnson, Mixing & Matching Covid-19 Vaccines, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Novavax, R&D, Therapeutics, Vaccines, Vaxzevria (previously COVID-19 Vaccine AstraZeneca)COVID-19 vaccine makers are shifting gears and planning for a smaller, more competitive booster shot market after delivering as many doses as fast as they could over the last 18 months.